Report : North America Pulmonary Arterial Hypertension Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded and Generics), Route of Administration (Oral, Intravenous/Subcutaneous, and Inhalational), and Distribution Channel (Hospital Pharmacies and Clinics, Online Pharmacies, and Retail Pharmacies)

At 6.0% CAGR, the North America Pulmonary Arterial Hypertension Market is speculated to be worth US$ 4,456.90 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the North America pulmonary arterial hypertension market was valued at US$ 3,147.76 million in 2022 and is expected to reach US$ 4,456.90 million by 2028, registering a CAGR of 6.0% from 2022 to 2028. Growing incidence of pulmonary arterial hypertension and rising approvals of pulmonary arterial hypertension drugs are the critical factors attributed to the North America pulmonary arterial hypertension market expansion.

In pulmonary arterial hypertension (PAH), tiny arteries in lung become thick and narrow. PAH blocks the blood flow through lungs. As a result, blood pressure in the lungs increases, and heart faces difficulties to pump blood through narrowed arteries. Over the time, an individual's heart loses the ability to pump blood throughout the body effectively. PAH usually affects women in the age range from 30 to 60 years. National Organization for Rare Disorders (NORD) stated that the case of PAH is 3–5 times higher in females than in males. Also, in the US, new cases are projected to occur in one to two people per million per year. The incidence is projected to be the same in Europe. About 500–1000 new cases of PAH are diagnosed annually in the US. Thus, the growing incidence of pulmonary arterial hypertension is driving the growth of the North America pulmonary arterial hypertension market.  

On the contrary, side effects of drugs used for treatment of pulmonary arterial hypertension hurdles the growth of North America pulmonary arterial hypertension market.

Based on drugs, the North America pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (eras), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. The prostacyclin and prostacyclin analogs segment held 38.6% share of North America pulmonary arterial hypertension market in 2022, amassing US$ 1,214.22 million. It is projected to garner US$ 1,801.03 million by 2028 to expand at 6.8% CAGR during 2022–2028.

Based on type, the North America pulmonary arterial hypertension market is bifurcated into branded and generics. The branded segment held 68.6% share of North America pulmonary arterial hypertension market in 2022, amassing US$ 2,159.61 million. It is projected to garner US$ 3,100.05 million by 2028 to expand at 6.2% CAGR during 2022–2028.  

Based on route of administration, the North America pulmonary arterial hypertension market is segmented into oral, intravenous/ subcutaneous, and inhalational. The oral segment held 48.2% share of North America pulmonary arterial hypertension market in 2022, amassing US$ 1,515.74 million. It is projected to garner US$ 2,216.59 million by 2028 to expand at 6.5% CAGR during 2022–2028.

Based on distribution channel, the North America pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. The hospital pharmacies and clinics segment held 43.8% share of North America pulmonary arterial hypertension market in 2022, amassing US$ 1,379.92 million. It is projected to garner US$ 2,028.94 million by 2028 to expand at 6.6% CAGR during 2022–2028.

Based on country, the North America pulmonary arterial hypertension market has been categorized into the US, Canada, and Mexico.  Our regional analysis states that the US captured 66.5% share of North America pulmonary arterial hypertension market in 2022. It was assessed at US$ 2,091.69 million in 2022 and is likely to hit US$ 3,019.55 million by 2028, exhibiting a CAGR of 6.3% during the forecast period.  

Key players profiles in  the North America pulmonary arterial hypertension market report are Aerami Therapeutics Holdings Inc; Bayer AG; Gilead Sciences Inc; GSK Plc; Johnson & Johnson; Lupin Ltd; Novartis AG; Pfizer Inc; Teva Pharmaceutical Industries Ltd; and United Therapeutics Corp among others.

  • May-2022, United Therapeutics Corporation received the U.S. Food and Drugs Administration (FDA) approval of Tyvaso DPI (treprostinil) inhalation powder for treating PAH; WHO Group 1, and PH-ILD; WHO Group 3 to improve exercise ability. Tyvaso DPI represents a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler approved by the FDA for use in PAH and PH-ILD.
  • Apr-2021, United Therapeutics Corporation received the U.S. Food and Drugs Administration (FDA) approval for Tyvaso (treprostinil) Inhalation Solution for the treatment of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. It is the second FDA-approved indication for Tyvaso, which was first approved in July 2009 for treating pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com

Download Free PDF Brochure